Literature DB >> 3919327

Serum alpha-1-acid glycoprotein in chronic renal failure.

D Docci, R Bilancioni, E Pistocchi, G Mosconi, F Turci, G Salvi, L Baldrati, C Orsi.   

Abstract

We measured the serum concentration of alpha-1-acid glycoprotein (AAG) in 30 healthy subjects (controls), in 54 patients with various degrees of residual renal function (group I), and in 98 patients in the terminal phase of chronic renal failure (CRF) on both conservative and dialytic therapy (group II). A positive correlation between the logarithm of serum AAG and serum creatinine levels was found in group I. Serum AAG increased significantly when serum creatinine rose above 10 mg/dl. This fact would indicate that a retention of the substance occurs as the renal function falls. The mean serum concentration of AAG was significantly higher in group II patients, with no difference between those on conservative therapy and those on maintenance hemodialysis. However, levels above normal were present in only a minority of cases. We conclude that the serum AAG measurement maintains its diagnostic value as an acute phase reactant also in the terminal phase of CRF.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3919327     DOI: 10.1159/000183364

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  6 in total

1.  Influence of continuous ambulatory peritoneal dialysis on serum alpha 1-acid glycoprotein concentration and drug binding.

Authors:  F M Belpaire; E J Van de Velde; N H Fraeyman; M G Bogaert; N Lameire
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man.

Authors:  E Snoeck; A Van Peer; M Sack; M Horton; G Mannens; R Woestenborghs; R Meibach; J Heykants
Journal:  Psychopharmacology (Berl)       Date:  1995-12       Impact factor: 4.530

3.  Association of Pulmonary Hypertension With Inflammatory Markers and Volume Status in Hemodialysis Patients of End-Stage Renal Disease.

Authors:  Satyendra K Sonkar; Mahboob Alam; Sharad Chandra; Gyanendra K Sonkar; Anil Gaikwad; Vivek Bhosale
Journal:  Cureus       Date:  2021-03-01

4.  Serum alpha 1 antichymotrypsin concentration as a marker of disease activity in rheumatoid arthritis.

Authors:  M D Chard; J Calvin; C P Price; T E Cawston; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1988-08       Impact factor: 19.103

Review 5.  Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity.

Authors:  G R Matzke; R F Frye
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

6.  Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment.

Authors:  Ken Ogasawara; William B Smith; Christine Xu; Jian Yin; Maria Palmisano; Gopal Krishna
Journal:  Cancer Chemother Pharmacol       Date:  2020-05-24       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.